Are you Dr. Ramirez?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 55 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
700 Childrens Dr
Columbus, OH 43205Phone+1 614-722-5315Fax+1 614-722-3033
Summary
- Dr. Nilsa Ramirez, MD is a board certified pathologist in Columbus, Ohio. She is currently licensed to practice medicine in Ohio and Michigan. She is affiliated with Nationwide Children's Hospital and The OSUCCC - James.
Education & Training
- Detroit Medical Center/Wayne State UniversityResidency, Pathology-Anatomic and Clinical, 1985 - 1990
- University of Puerto Rico School of MedicineClass of 1985
Certifications & Licensure
- OH State Medical License 2001 - 2026
- MI State Medical License 1988 - 2025
- American Board of Pathology Anatomic Pathology
Clinical Trials
- Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Publications & Presentations
PubMed
- 4386 citationsComprehensive molecular characterization of gastric adenocarcinomaAdam J. Bass, Vesteinn Thorsson, Ilya Shmulevich, Sheila Reynolds, Michael Miller
Nature. 2014-09-11 - 3666 citationsIntegrated genomic characterization of endometrial carcinomaGad Getz, Stacey Gabriel, Kristian Cibulskis, Eric S. Lander, Andrey Sivachenko
Nature. 2013-05-02 - 8236 citationsComprehensive molecular portraits of human breast tumoursDaniel C. Koboldt, Robert S. Fulton, Michael D. McLellan, Heather Schmidt, Joelle Kalicki-Veizer
Nature. 2012-10-04
Press Mentions
- Initiative Seeks to Improve Solid Tumor Treatment and Diagnosis in ChildrenApril 27th, 2022
- Cloud-Based Digital Pathology Startup Deep Lens Exits Stealth Mode with $3.2 Million Seed FinancingOctober 12th, 2018
- Biospecimen Core Resource Wins NIH Contract to Further Cancer ResearchFebruary 20th, 2018